Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
Martins-Branco D, Nader-Marta G, Molinelli C, Ameye L, Paesmans M, Ignatiadis M, Aftimos P, Salgado R, de Azambuja E. Martins-Branco D, et al. Among authors: aftimos p. Eur J Cancer. 2023 Nov;194:113358. doi: 10.1016/j.ejca.2023.113358. Epub 2023 Sep 22. Eur J Cancer. 2023. PMID: 37857118
[Chemoradiotherapy in early stage Hodgkin's lymphoma].
Farha G, Nasr E, Ghosn M, Nasr DN, Nasr F, Kattan J, Azoury F, Aftimos P, Chahine G. Farha G, et al. Among authors: aftimos p. J Med Liban. 2011 Jul-Sep;59(3):122-5. J Med Liban. 2011. PMID: 22259898 French.
Successful treatment of Evans syndrome with Tacrolimus.
Tabchi S, Hanna C, Kourie HR, Aftimos P, El Osta L, Ghosn M. Tabchi S, et al. Among authors: aftimos p. Invest New Drugs. 2015 Feb;33(1):254-6. doi: 10.1007/s10637-014-0155-9. Epub 2014 Sep 12. Invest New Drugs. 2015. PMID: 25209619 No abstract available.
A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.
Ghosn M, Aftimos P, Farhat FS, Kattan JG, Hanna C, Haddad N, Nasr F, Chahine G. Ghosn M, et al. Among authors: aftimos p. Med Oncol. 2011 Dec;28 Suppl 1:S142-51. doi: 10.1007/s12032-010-9754-2. Epub 2010 Dec 7. Med Oncol. 2011. PMID: 21136213 Clinical Trial.
The clinical impact of using complex molecular profiling strategies in routine oncology practice.
Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayyat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H. Laes JF, et al. Among authors: aftimos p. Oncotarget. 2018 Apr 17;9(29):20282-20293. doi: 10.18632/oncotarget.24757. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755651 Free PMC article.
Cardiotoxicity of systemic agents used in breast cancer.
Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, de Azambuja E. Ades F, et al. Among authors: aftimos p. Breast. 2014 Aug;23(4):317-28. doi: 10.1016/j.breast.2014.04.002. Epub 2014 May 1. Breast. 2014. PMID: 24794210 Free article. Review.
94 results